logo
Overview
Discover
Watchlists
Portfolios
Heatmap
Sectors
Trendscore
Performers
Alerts
Options
Earnings
Screeners
Scanners
Backtests
Strategies
Comparisons
Charts
Sign in
Discover

AGEN
Agenus Inc.
3.41
2 x 2.40
2 x 3.91
bid
ask
+
0.35
11.44%
2 @ 04:00 PM
3.40 -0.01 (0.29%)
Ytd8.60%
1y-29.55%
3.06
day range
3.42
2.71
52 week range
7.34
Open3.06Prev Close3.06Low3.06High3.42Mkt Cap142.00M
Vol659.40KAvg Vol942.68KEPS2.05P/E1.66Forward P/E-0.28
Beta1.39Short Ratio4.16Inst. Own37.10%DividendN/ADiv YieldN/A
Ex Div DateN/AEarning08-1050-d Avg3.42200-d Avg3.671yr Est8.00

AGEN News

Agenus Announces Three-Year Survival Data from Phase 1b BOT+BAL Study in MSS Metastatic Colorectal Cancer to be Presented at ESMO GI 2026
gurufocus.com
Agenus Announces Three-Year Survival Data from Phase 1b BOT+BAL Study in MSS Metastatic Colorectal C

[url="]Agenus[/url] Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced tha

benzinga.com
Agenus To Present 3-Yr Survival Data From Phase 1b C-800-01 Study Of Botensilimab Plus Balstilimab I

Data reflect an additional year of follow-up from the 123-patient cohort in the Phase 1b studyAgenus

Agenus Announces Three-Year Survival Data from Phase 1b BOT+BAL Study in MSS Metastatic Colorectal Cancer to be Presented at ESMO GI 2026
businesswire.com
Agenus Announces Three-Year Survival Data from Phase 1b BOT+BAL Study in MSS Metastatic Colorectal C

LEXINGTON, Mass.--(BUSINESS WIRE)--Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovatio